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Background: Recent studies have demonstrated a superior diagnostic accuracy of cardiovascular magnetic
resonance (CMR) for the detection of coronary artery disease (CAD). We aimed to determine the comparative
cost-effectiveness of CMR versus single-photon emission computed tomography (SPECT).
Methods: Based on Bayes’ theorem, a mathematical model was developed to compare the cost-effectiveness and
utility of CMR with SPECT in patients with suspected CAD. Invasive coronary angiography served as the standard of
reference. Effectiveness was defined as the accurate detection of CAD, and utility as the number of quality-adjusted
life-years (QALYs) gained. Model input parameters were derived from the literature, and the cost analysis was
conducted from a German health care payer’s perspective. Extensive sensitivity analyses were performed.
Results: Reimbursement fees represented only a minor fraction of the total costs incurred by a diagnostic strategy.
Increases in the prevalence of CAD were generally associated with improved cost-effectiveness and decreased costs
per utility unit (ΔQALY). By comparison, CMR was consistently more cost-effective than SPECT, and showed lower
costs per QALY gained. Given a CAD prevalence of 0.50, CMR was associated with total costs of €6,120 for one
patient correctly diagnosed as having CAD and with €2,246 per ΔQALY gained versus €7,065 and €2,931 for SPECT,
respectively. Above a threshold value of CAD prevalence of 0.60, proceeding directly to invasive angiography was
the most cost-effective approach.
Conclusions: In patients with low to intermediate CAD probabilities, CMR is more cost-effective than SPECT.
Moreover, lower costs per utility unit indicate a superior clinical utility of CMR.
Keywords: Cost-effectiveness, Cardiovascular magnetic resonance, Scintigraphy, Coronary angiography,
Coronary artery diseaseBackground
Coronary artery disease (CAD) is a major cause of death
and disability in developed countries and can be consid-
ered as a global public health challenge [1,2]. Given its
prevalence and related morbidity, the total economic
burden of CAD is enormous [3]. Diagnostic strategies
that allow an early and accurate diagnosis of CAD are* Correspondence: marc.dorenkamp@charite.de
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reproduction in any medium, provided the ortherefore highly desirable, both medically and economic-
ally [4].
Imaging tests have significantly improved the detection
of CAD, with single-photon emission computed tomog-
raphy (SPECT) being one of the most commonly used
methods [5]. Although widely available, SPECT has its
limitations, such as a relatively low spatial resolution
and patient exposure to ionizing radiation [6]. In recent
years, cardiovascular magnetic resonance (CMR) has
emerged as an important imaging modality for the non-
invasive assessment of CAD [7-9]. Potential advantagestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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spatial resolution, and versatile imaging capabilities
which allow visualizing different pathological aspects of
CAD during a single patient examination (e.g. myocar-
dial viability, cardiac function and morphology) [10,11].
Earlier studies have evaluated the diagnostic accuracy of
stress-perfusion CMR for the detection of CAD and
some studies have reported equal or improved results
compared with SPECT [12-16]. However, the findings of
a recent trial, which exploited the full potential of CMR,
demonstrated a superior diagnostic accuracy of CMR
compared with SPECT [17].
As the costs of CMR may significantly exceed the costs
associated with SPECT, the economic effect of CMR must
be considered [18]. The present study therefore aimed to
determine the cost-effectiveness of CMR as an alternative
to SPECT in patients with suspected CAD.
Methods
Study design
Based on Bayes’ theorem, a previously described math-
ematical model was used to determine the comparative
cost-effectiveness and utility of the following three ap-
proaches for diagnosing CAD: (1) CMR, (2) SPECT, and
(3) invasive coronary angiography [19-21]. The effective-
ness data and other model input parameters were derived
from the literature.
Effectiveness of tests
Effectiveness of diagnostic tests was defined in two ways.
The first effectiveness criterion was the ability of a diag-
nostic test to accurately identify a patient with CAD
[19-22]. This definition represents a straightforward
approach assuming that the single goal of a test is to
make a diagnosis [19-21]. The definition of the second
effectiveness criterion was more complex and attempted
to account for the future health outcome of patients
undergoing the tests (i.e., clinical utility) [19,20]. It was
assumed that a correct diagnosis of CAD would enable
patients to receive optimal therapy resulting in improved
survival and well-being. Over the follow-up period, the
number of life-years gained (Δ) by CAD therapy was
adjusted for quality of life, yielding quality-adjusted life-
years (QALYs). By convention, utility or quality of life
scores are expressed on a scale from 0 to 1, with 0 being
equivalent to death and 1 being a state of perfect health.
QALYs are calculated by multiplying the length of time
spent in a particular disease state by the utility associ-
ated with that disease state. In line with previous cost-
effectiveness analyses, an accurate diagnosis of CAD was
projected to increase the number of QALYs by 3 years
during a 10-year follow-up [20]. Equations and details of
the underlying calculations can be found elsewhere
[19,20]. The follow-up was limited to 10 years forpurposes of conservative estimation [19,20]. Importantly,
the computed increase in QALYs (ΔQALY) is only used
as a common denominator to facilitate a comparison of
cost per utility unit of different tests to diagnose CAD
[19,20]. Rather than calculating the absolute cost of each
diagnostic test, the present study was designed to com-
pare the rank order of cost per utility unit of the evalu-
ated tests [19,20].
Diagnostic procedures
It was assumed that CMR was performed on a 1.5 Tesla
scanner and that the imaging protocol consisted of myo-
cardial rest and adenosine stress perfusion imaging, late
gadolinium enhancement, and left ventricular cine im-
aging [17]. Data on the diagnostic accuracy of CMR
were derived from the recently published CE-MARC
(Clinical Evaluation of Magnetic Resonance imaging in
Coronary heart disease) trial, after excluding non-
invasive coronary angiography data from the analysis
(Table 1) [17]. The CE-MARC trial included 752 patients
with an estimated prevalence of significant CAD of 40-
60%. All patients were scheduled for CMR and SPECT,
followed by invasive coronary angiography [17]. The rate
of severe complications related to CMR was taken from
the EuroCMR (European CMR) registry [23]. Due to the
lack of data, the procedure-related mortality rate of
CMR was assumed to be the same as for exercise stress
testing [19,20,24]. In the base case scenario, the rate of
non-diagnostic CMR examinations was set at 5% [17,25].
In line with the CE-MARC trial, SPECT imaging was
assumed to be performed with a dual-head gamma cam-
era using a standard 99mTechnetium-based 2-day proto-
col, as advised in current guidelines [17,26,27]. Rest and
stress electrocardiographically (ECG)-gated SPECT im-
ages were acquired using an adenosine protocol identical
to the one used for CMR [17]. As for CMR, the diagno-
sis of CAD incorporated all available data (i.e., perfusion
during rest and stress conditions, cardiac wall motion
analysis, and left ventricular volumes). Overall accuracy
of SPECT for the diagnosis of CAD was again taken
from the CE-MARC trial [17]. Data on serious complica-
tions and mortality due to SPECT were derived from
previously published cost-effectiveness analyses on car-
diac SPECT imaging [19,20,24]. The rate of non-
diagnostic examinations was assumed to be the same as
for CMR imaging [17,20,25]. Detailed descriptions of
both the CMR and SPECT imaging protocols are given
elsewhere [17].
Invasive coronary angiography using standard tech-
niques constituted the standard of reference. Clinically
significant CAD was defined as the presence of a coron-
ary stenosis of 70% or more in at least one major coron-
ary artery, or 50% stenosis in the left main stem [17]. By
definition, invasive angiography represented a perfect
Table 1 Model input parameters
Parameter Value Range Ref.
SnC Sensitivity of CMR 0.82 0.77-0.86 [17]
SpC Specificity of CMR 0.86 0.82-0.89 [17]
SnS Sensitivity of SPECT 0.67 0.60-0.72 [17]
SpS Specificity of SPECT 0.83 0.79-0.86 [17]
SnA Sensitivity of angiography 1.00 N/A [19-21]
SpA Specificity of angiography 1.00 N/A [19-21]
RC Complication rate with CMR 0.0005 0.0001-0.001 [23]
RS Complication rate with SPECT 0.0005 0.0001-0.001 [20]
RA Complication rate with angiography 0.005 0.001-0.01 [28]
RF Complication rate for patients with CAD and false-negative test results* 0.25 0.15-0.30 [20,21]
MC Mortality rate due to CMR 0.00005 0.00001-0.0001 [20,24]
MS Mortality rate due to SPECT 0.00005 0.00001-0.0001 [20,24]
MA Mortality rate due to angiography 0.00075 0.0001-0.0015 [28]
MF Mortality rate for patients with CAD and false-negative test results* 0.20 0.15-0.25 [19,20]
NDxC Rate of non-diagnostic CMR 0.05 0.01-0.1 [17,25]
NDxS Rate of non-diagnostic SPECT 0.05 0.01-0.1 [17,25]
NDxA Rate of non-diagnostic angiography 0.00 N/A [19-21]
CC Cost of CMR [in €] 703 527-879 [31,34]
CS Cost of SPECT [in €] 504 378-630 [30,33]
CA Cost of angiography [in €] 2,926 2,195-3,658 [29,35]
C Cost of a complication# [in €] 14,478 10,859-18,098 [21,36]
NC No. of patients having CMR 1.0 N/A [21]
NS No. of patients having SPECT 1.0 N/A [21]
NA No. of patients having angiography varies Equation 1a [19-21]
NFC No. of false-negative CMR varies Equation 1a [19-21]
NFS No. of false-negative SPECT varies Equation 1a [19-21]
P Prevalence of CAD varies 0.1-1.0 [19-21]
ΔQALY’ QALY extended by CAD therapy* 3.0 2.0-4.0 [20]
ΔQALY Net QALY gained varies Equations 1c,2c [20]
*Over a 10-year follow-up period.
#Assumed to be myocardial infarction (or cerebral, for invasive angiography).
Angiography refers to invasive coronary angiography. Details of the parameters are given in the text.
CAD: coronary artery disease; CMR: cardiovascular magnetic resonance; N/A: not applicable; QALY: quality-adjusted life-year; SPECT: single-photon emission
computed tomography.
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out any non-diagnostic results [19-21]. The rates of compli-
cation and mortality for patients undergoing invasive
coronary angiography were derived from the literature [28].
Costs
Economic analyses were conducted from the perspective
of a health care payer (German health care insurance
system). Cost data were obtained from multiple sources,
including the 2012 version of the German Diagnosis
Related Groups (G-DRG) system, the Uniform Value
Scale (Einheitlicher Bewertungsmaßstab, EBM), and the
German doctor’s fee schedule (Gebührenordnung fürÄrzte, GOÄ) (Table 1) [29-31]. Both, SPECT and CMR
were considered as outpatient tests, while invasive cor-
onary angiography was considered an inpatient proced-
ure [18]. According to the EBM catalogue, and a
monetary point value of €0.032, the costs of SPECT
amounted to €504 (EBM reimbursement codes 17210,
17330, 17331, 17333, 17363, 40520, and 40522)
[30,32,33]. In the EBM system, CMR cannot yet be
coded as a specific examination and costs of CMR are
not covered adequately with existing reimbursement
options for thoracic magnetic resonance imaging (€204
including a lump sum of €50 for contrast agent) [18,34].
Thus, we opted to calculate the costs of a CMR study
Figure 1 Diagnostic algorithms. Diagnostic algorithms for patients
(Pt) presenting with suspected coronary artery disease (CAD). In
algorithm A, cardiovascular magnetic resonance (CMR) was performed
first and patients were referred for invasive coronary angiography
(Angio) only if CMR was positive or non-diagnostic (NDx). Patients with
false-negative test results were at risk for myocardial (MI) or death from
undetected CAD. Diagnostic algorithm B had the same basic structure
as algorithm A, but involved single-photon emission computed
tomography (SPECT) instead of CMR. Algorithm C used invasive
coronary angiography as the first and only test to diagnose CAD.
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codes 200, 271, 346, 347, 602, 5715, 5731, and 5733)
[31,34]. The basic costs given in the GOÄ catalogue can
be multiplied by a specific factor, for instance up to 1.8
for radiological examinations, if the procedure was more
complicated than average or if both the patient and
physician have agreed beforehand that a multiplication
factor will be applicable [31]. For calculation purposes,
averages of the basic and the maximum costs were taken
for each GOÄ code. Including a fee of €150 for material
costs, CMR costs totaled €703 (Table 1). Costs for inva-
sive coronary angiography were calculated as the average
of the G-DRGs F49B, F49E, and F49G with a base rate
of €2,970 (Table 1) [29,35]. Conservative cost estimates
for a major complication amounted to €14,478 [21,36].
All costs were given in Euro (€) and were rounded to
the nearest whole amount.
Calculation of cost-effectiveness and utility
Total costs were calculated by multiplying direct costs
with the number of patients tested plus the induced
costs. Cost-effectiveness was calculated as cost per effect
[19-21]:
Direct Costsþ Induced Costs
Effectiveness
In this respect, direct costs reflected the fees for diag-
nostic tests, as given in Table 1. Induced costs included
cost of complications associated with the test procedures
or false-negative CAD results multiplied by the number
of patients tested as well as subsequent testing triggered
by the results of the first test (e.g. invasive coronary
angiography after a positive result of CMR or SPECT)
[19-21]. Effectiveness was a patient with CAD diagnosed.
The utility of a test was its ability to add a number of
QALYs over a 10-year follow-up period [19,20]. In the
diagnostic algorithms involving CMR (Figure 1A) or
SPECT (Figure 1B), CMR or SPECT were performed
first and were followed by invasive angiography but only
if non-invasive testing showed positive results or was
non-diagnostic [21]. Specifically, calculations of cost-
effectiveness and utility involved the equations below
(Table 1 shows parameters used in equations) [19-21]:
1. CMR (or SPECT)
a) Costs =NC · (CC + RC · C) +NA · (CA + RA · C) +NFC ·(RF ·C)whereas
NA =NC · (1 −NDCxC) · [P · SnC + (1 − P) ·
(1 − SpC)] +NC ·NDxC and NFC =NC ·
(1 −NDxC) · P · (1 − SnC)b) Effectiveness =NC · (1 −NDxC) · P · SnC +NC · P ·
NDxCc) ΔQALY = (CADDx) · (ΔQALY ') − 10 · (NC ·MC +NA ·
MA) − 5 · (NFC ·MF) − 10 · (0.1) · (NC · RC +
NA · RA +NFC · RF)Equations 1a-c were used for both CMR and SPECT.
For space reasons, only the CMR equations are shown.
Application to SPECT required replacing CMR-specific
with SPECT-specific variables (Table 1). Equation 1c, the
formula to calculate net QALYs gained (ΔQALY), assumed
that deaths caused by diagnostic tests subtract 10 years,
and deaths due to false-negative test results and hence
missed CAD subtract 5 years on average [20]. Complica-
tions caused by diagnostic testing or by missed CAD were
assumed to reduce the quality of life by 1/10 per annum.
In the final diagnostic algorithm, invasive coronary
angiography was the first and only diagnostic test to
evaluate patients for suspected CAD (Figure 1C). The
following equations were applied (parameters are given
in Table 1) [19-21]:
2. Invasive coronary angiography
a) Costs =NA · (CA + RA ·C)
whereas
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b) Effectiveness =NA · P
c) ΔQALY =NA · ΔQALY ' · P − 10 ·NA ·MA −NA · RAData and sensitivity analysis
A one-way sensitivity analysis was performed to evaluate
whether the results of the base case scenario were
affected by changes in the model input parameters. The
variables were changed over the ranges given in Table 1.
Most important, the diagnostic sensitivities and specific-
ities of CMR and SPECT were increased and decreased
according to the 95% confidence intervals given in the
CE-MARC trial [17]. All costs were varied by 25% in
each direction (Table 1) [37]. Rates of non-diagnostic
CMR and SPECT examinations were changed to 1% and
10%, respectively. The impact of different clinical out-
comes on model results was analyzed by varying compli-
cation rates, 10-year follow-up estimates, and the value
of ΔQALY (Table 1). All analyses were performed with
Excel for Windows (Microsoft Office 2010, Microsoft
Corp., Redmond, WA, USA).Results
Impact of CAD prevalence on total costs, cost-
effectiveness and utility
Direct costs of CMR and SPECT, which were reflected
by the reimbursement fees given in Table 1, represented
only a minor fraction of the total costs incurred by the
respective diagnostic strategy (Figure 2A). Prevalence of
CAD was varied between 0.10 and 1.0 in increments of
0.10. When set in relation to different prevalences of
CAD, total costs of CMR and SPECT increased as a
linear function of disease prevalence (Figure 2A). In con-
trast, costs did not increase significantly for invasive cor-
onary angiography. At a CAD prevalence <0.70, both
non-invasive tests were associated with lower total costs
than invasive coronary angiography but with higher
costs at higher prevalences of CAD (≥0.70). Figure 2B
plots cost per effect (defined as accurate diagnosis of
CAD) versus prevalence of CAD. All three diagnostic
strategies exhibited hyperbolic decreases in cost per ef-
fect with increasing CAD prevalences. Because cost per
effect is the inverse of cost-effectiveness, this decrease
indicates increased cost-effectiveness. Likewise, as the
prevalence of CAD increased, there were decreased costs
per utility unit in terms of QALYs gained (Figure 2C)
Δindicating increased cost-utility at higher disease preva-
lences. Thus, despite the fact that total costs increased
with increasing prevalence of CAD (Figure 2A), cost per
effect and cost per utility improved. The hyperbolic rela-
tionship between CAD prevalence and cost per effect orcost per utility implicates very high costs per effect or
utility unit at low disease prevalences (Figure 2B and C).
Comparison of diagnostic strategies – CMR versus SPECT
Differences between CMR and SPECT with respect to
cost per effect and cost per utility unit were analyzed at
varied prevalences of CAD. Results of these comparisons
are exemplified for low (0.20), intermediate (0.50), and
high (0.80) disease prevalences in Table 2. In populations
with a low prevalence of CAD (e.g. 0.20), CMR is the
most cost-effective diagnostic approach (i.e. lowest cost
per effect), followed by SPECT and with a significant
difference by invasive coronary angiography (Figure 2B).
At a disease prevalence of 0.50, CMR remained the most
cost-effective approach, while SPECT became least cost-
effective and the differences among the three diagnostic
strategies were less dramatic. In a population with a high
CAD prevalence (e.g. 0.80), invasive coronary angiog-
raphy was most cost-effective. However, the rank order
between CMR and SPECT never changed (Figure 2B)
and CMR was always more cost-effective and exhibited
lower costs per effect than SPECT (indicated by minus-
signs in Table 2). At a low prevalence of CAD (0.20), the
rank order of cost per utility unit was principally the
same as that of cost per effect (Figure 2C). Again, the
rank order of tests changed at an intermediate disease
prevalence and performing invasive coronary angiog-
raphy as the first and only test was the most cost-
effective diagnostic approach at high disease prevalences
(e.g. 0.80) (Figure 2C). Despite lower direct costs (i.e.,
fee for diagnostic testing; Table 1), SPECT was always
linked to higher total costs per utility unit than CMR
(denoted by minus-signs in the far right column in
Table 2). The similarity of the graphs displaying cost per
effect (Figure 2B) and cost per utility unit (Figure 2C) is
indicative of the robustness of the employed mathemat-
ical model.
Sensitivity analyses
Assuming base-case values and given a CAD prevalence
of 0.50, CMR was associated with total costs of €6,120
for one patient correctly diagnosed as having CAD and
with €2,246 per ΔQALY gained versus €7,065 and €2,931
for SPECT, respectively. Differences were calculated by
subtracting the results for SPECT from those for CMR
and amounted to -€945 per effect (accurate diagnosis of
CAD) and to -€685 per utility unit (ΔQALY) (Table 2).
These base-case results were robust to plausible alterna-
tive scenarios as sensitivity analyses showed that CMR
would remain more cost-effective than SPECT through
the whole range of parameter estimates (Table 1). Figure 3
presents the results of deterministic one-way sensitivity
analyses performed at a prevalence of CAD of 0.50. For
clarity, the results are graphically displayed through the
Figure 2 Effect of CAD prevalence on costs, cost-effectiveness and utility. In each of the three graphs, prevalence of coronary artery disease
(CAD) increases along the horizontal axis. In all cases, costs are given in Euro. The upper graph (A) shows the total cost per patient (Pt) tested on
the vertical axis for cardiovascular magnetic resonance (CMR), single-photon emission computed tomography (SPECT), and invasive coronary
angiography (Angio). Costs increase significantly with CAD prevalence for CMR and SPECT, but not for invasive angiography. Cost per effect, in
terms of cost per accurate diagnosis (Dx) of CAD, is depicted in the middle graph (B). The decrease of cost per effect with growing CAD
prevalence indicates growing cost-effectiveness as cost per effect is the inverse of cost-effectiveness. The lower graph (C) plots cost per utility
unit, in terms of quality-adjusted life-years gained (ΔQALY), on the vertical axis. Cost per utility unit decreases as prevalence of CAD increases.
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that influence the base-case results most, arranged from
top to bottom according to their importance. Figure 3A
illustrates that the sensitivity of SPECT, costs of SPECT
and CMR, the sensitivity of CMR, and the average costof a complication were the most influential parameters
on the cost per effect difference between CMR and
SPECT. The results of the sensitivity analysis to investi-
gate the impact of parameter variation on the cost per
utility difference between CMR and SPECT are shown
Table 2 Health and economic outcomes
Difference between CMR and SPECT
Prevalence of CAD Test Total cost (€) Effect (CAD Dx) Utility (ΔQALY) Cost per effect (€/CAD Dx) Cost per utility (€/ΔQALY)
0.20 CMR 1,770 0.17 0.45
SPECT 1,657 0.14 0.33 −1,394 −1,106
0.50 CMR 2,537 0.41 1.13
SPECT 2,425 0.34 0.83 −945 −685
0.80 CMR 3,304 0.66 1.81
SPECT 3,193 0.55 1.33 −811 −563
CAD: coronary artery disease; Dx: accurate diagnosis (of CAD); CMR: cardiac magnetic resonance; QALY: quality-adjusted life-year; SPECT: single-photon emission
computed tomography.
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the amount of QALYs extended by CAD therapy over a
10-year follow-up period, the sensitivities of SPECT and
CMR, costs of SPECT and CMR, and the average cost
of a complication. For both cost per effect and cost per
utility unit, results were least sensitive to variations in
the values of complication rates with SPECT and CMRFigure 3 Sensitivity analyses. Tornado diagrams displaying the results of
cost per utility unit (B) determined at a prevalence of coronary artery disea
axis intersects the horizontal axis at the base-case cost per effect (−€945/ac
quality-adjusted life-years; ΔQALY) difference between cardiovascular magn
tomography (SPECT). The width of each horizontal bar illustrates the impac
to either side of a bar represent the highest or lowest value simulated for e
year follow-up apply to patients with false-negative test results. For input v(data not shown). Nonetheless, for all parameters tested
in the sensitivity analysis, the differences in cost per ef-
fect and cost per utility unit can be considered as eco-
nomically attractive in favor of CMR. Sensitivity
analyses also indicated that above a threshold value of
CAD prevalence of 0.60, proceeding directly to invasive
angiography was the most cost-effective approach.deterministic one-way sensitivity analyses of cost per effect (A) and
se (CAD) of 0.50. Each bar represents a sensitivity variable. The vertical
curate diagnosis of CAD) or cost per utility unit (−€685/increase in
etic resonance (CMR) and single-photon emission computed
t of the respective parameter on base-case results. The values adjacent
ach model input parameter. Complication or mortality rates per 10-
ariables, see Table 1.
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Main findings
To the best of our knowledge, this is the first study to
systematically evaluate the cost-effectiveness of CMR
compared with SPECT for diagnosing CAD in patients
suspected of having this disease. Calculations were
performed using a well-validated model based on the
equations of Bayes’ theorem and the cost-analysis was
conducted from a health care payer’s perspective. Com-
pared to SPECT, CMR resulted in relatively better cost-
effectiveness and utility across all prevalence levels and
the full range of sensitivity analyses. Cost-effectiveness
was influenced mostly by varying the sensitivities of
CMR and SPECT, the costs associated with both diag-
nostic tests, and the average cost of a complication. The
same factors, supplemented by the amount of QALYs
extended by CAD therapy over a 10-year follow-up
period, had the largest impact on cost per utility differ-
ences between CMR and SPECT. Above a threshold
value of CAD prevalence of 0.60, proceeding directly to
invasive angiography was found to be the most cost-
effective diagnostic strategy.
Assessment of cost-effectiveness and utility
In the past years, cost considerations have become in-
creasingly relevant in clinical decision making [38].
Cost-effectiveness analysis can help decision-makers to
allocate limited resources and can guide the utilization
of latest-generation and presumably high-cost imaging
modalities [39].
One of the key requirements of cost-effectiveness
analysis is the identification of all relevant costs. If the
analysis is carried out from the viewpoint of a health
care payer, procedure costs usually represent charges or
reimbursement fees [40]. The German health care sys-
tem is characterized by the presence of public and pri-
vate health insurers. Within the public system,
outpatient health care services such as SPECT are to be
charged according to the EBM system [30]. In the ab-
sence of a specific EBM procedure code for CMR, we
chose to use the GOÄ fee schedule for privately insured
patients. This is common practice in Germany, as the
GOÄ fees much better reflect the actual costs incurred
by CMR [31,34]. As a result, CMR was associated with
nearly 40% higher costs than SPECT (Table 1). Import-
antly, this cost ratio is very similar to cost ratios de-
scribed for the United States or the United Kingdom.
Because our model depends on relative rather than on
absolute costs, the results of the present study can be as-
sumed to be generally valid for other health care systems
as well [18]. As the study takes a health care payer’s and
not a societal perspective, other costs such as lost prod-
uctivity due to missed days at work (indirect costs) were
not included [21,40]. Rather than assessing the impact ofdiagnostic tests on the overall welfare of society, the goal
of the study was to compare the cost-effectiveness and
utility of CMR and SPECT to achieve the same object-
ive, i.e. diagnosing CAD and thereby improving the clin-
ical outcome [20,21]. The outcome variable was limited
to a 10-year follow-up underlining the conservative na-
ture of our analysis. If the effects of CAD therapy would
have been simulated beyond the 10-year horizon, than
the impact on outcome (ΔQALY) might have been even
more favourable than indicated by our results.
The diagnostic accuracy of CMR to detect CAD was
taken from the recently published CE-MARC study
which prospectively evaluated the role of CMR in pa-
tients with suspected CAD [17]. By comparison, CMR
delivered a higher sensitivity and specificity than SPECT
[17]. Another large study, MR-IMPACT II (Magnetic
Resonance Imaging for Myocardial Perfusion Assess-
ment in Coronary artery disease Trial II), also detailed
the accuracy of CMR compared with SPECT [25,41].
MR-IMPACT II confirmed CMR’s position as alternative
to SPECT with higher sensitivity to detect CAD. Unlike
CE-MARC, the specificity of CMR was inferior to
SPECT in MR-IMPACT II [25,41]. However, CE-MARC
had a more rigorous study design and included a larger
patient population [17,42]. Moreover, CE-MARC used
the full potential of CMR, including perfusion imaging,
late gadolinium enhancement, left ventricular cine im-
aging, and non-invasive coronary angiography while
MR-IMPACT II focused solely on perfusion abnormal-
ities [17,25,43]. Because coronary angiography by CMR
cannot be regarded as standard part of routine examina-
tions and because it is not feasible in all patients, it was
not incorporated in our analysis (Table 1). This exclu-
sion led to a slightly diminished diagnostic accuracy of
CMR, again reflecting the conservative estimates used in
our study [17]. It is noteworthy, that future imaging pro-
tocols may even further increase the diagnostic accuracy
of CMR [44]. Dobutamine stress CMR, while clinically
valuable, was not part of our analysis [45]. For
consistency and comparability, data on diagnostic accur-
acy of SPECT were also derived from the CE-MARC
study [17]. Although other studies have reported differ-
ent and wide varying diagnostic accuracies of SPECT,
the superior sensitivity of CMR in comparison to SPECT
seems to be a common finding [17,25,41,46]. With re-
spect to cost-effectiveness and utility, our results clearly
indicate that a high sensitivity is more important than a
high specificity (Figure 3A and B).
Although the cost per patient tested increased linearly
along the prevalence of CAD (Figure 2A), both cost-
effectiveness (cost per effect) and utility (cost per utility
unit) showed a hyperbolic decrease in costs (Figure 2B
and 2C). The observation that the effectiveness as well
as the utility criterion yielded concordant results
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costs is due to the fact that the underlying mathematical
model defines a patient accurately as having CAD as the
effect and an increase in QALYs (ΔQALY) as utility
[19-21]. Both effect and utility become more frequent
with an increase in CAD prevalence [19-21]. Specifically,
the effect (i.e., the diagnosis of CAD) was based on func-
tional testing (CMR and SPECT) [17,25]. In contrast, in-
vasive coronary angiography relies on morphological
criteria and direct visualization of the coronary arteries
and may therefore be an imperfect standard of reference.
Obviously, invasive fractional flow reserve is the most
accurate parameter to assess the functional relevance of
a stenosis, but those data were not available from CE-
MARC or other large comparative studies of CMR and
SPECT [17,47]. However, as coronary stenoses not caus-
ing ischemia may be judged as significant on the basis of
angiographic severity alone, the actual diagnostic accur-
acy and therefore the cost-effectiveness of CMR is prob-
ably even better than simulated by our model.
At low CAD prevalences, both non-invasive tests were
more cost-effective than invasive coronary angiography
(Figure 2A and 2B). This is because the majority of
negative CMR and SPECT examinations will correctly
rule out significant CAD at low disease prevalences and
will therefore reduce the number of invasive angiogra-
phies [18]. At higher disease prevalences, though, both
non-invasive tests (SPECT > CMR) start to miss patients
who actually have CAD. The consequences of such
false-negative test results decrease cost-effectiveness and
utility because they may prevent patients having CAD
from receiving adequate treatment. The lack of treat-
ment may lead to increased mortality, decreased quality
of life, and to additional costs related to complications
of CAD (i.e., treatment of myocardial infarction). False-
positive test results also lead to decreased cost-
effectiveness and utility, mainly due to overtreatment
and unnecessary invasive coronary angiographies.
In parallel, invasive coronary angiography as the initial
test becomes more competitive in terms of cost per ef-
fect and cost per utility. Sensitivity analyses indicated
that above a threshold value of CAD prevalence of 0.60,
performing invasive angiography was the most cost-
effective strategy. This threshold is in line with previous
cost-effectiveness analyses examining non-invasive strat-
egies to detect CAD [19-21,48,49]. In addition, recent
guidelines recommend invasive angiography as the most
cost-effective first test if the pretest probability of CAD
is >61% [50].
Our study has some limitations. Firstly, our model
necessarily simplifies some aspects of the underlying
clinical reality and does not account for all complica-
tions associated with CMR (e.g. gadolinium-associated
nephrogenic systemic fibrosis) or SPECT (e.g. radiation-induced malignancies) [23,49]. Secondly, diagnostic
accuracy data were derived from studies with an inter-
mediate prevalence of CAD. Extrapolation of these data
to populations with high or low disease prevalences
should be judged with caution. Thirdly, the analysis of
further imaging modalities (e.g. computed tomography
or stress echocardiography) was beyond the scope of the
present study. Furthermore, coronary revascularization
was not within the scope of the current analysis.
Conclusions
In patients with low to intermediate pretest probabilities,
CMR is more cost-effective for the detection of CAD
than SPECT. The superior diagnostic accuracy of CMR
also leads to an improved clinical utility as indicated by
lower costs per number of QALYs gained. Above a
threshold value of CAD prevalence of 0.60, proceeding
directly to invasive angiography was found to be the
most cost-effective diagnostic strategy. Generally, an
intermediate pretest likelihood ranges from 20-80% and
there may be situations in which the likelihood of CAD
exceeds 0.60, and CMR is no longer cost-effective. Thus,
the most crucial step for physicians in selecting the ap-
propriate diagnostic strategy in patients with suspected
CAD is based on disease likelihood as estimated by
clinical symptoms and the presence of cardiovascular
risk factors.
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